Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis

Chen, Zhongyun; Liu, Chunyan; Zhang, Jie; Relkin, Norman; Xing, Yan; Li, Yanfeng

doi:10.1186/s12987-017-0062-5

Fluids and Barriers of the CNS

Table 1 Characteristics of studies included in the meta-analysis

From: Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis

Study	Country	Patients	N	Age	Male	Aβ42 (pg/ml)	t-tau (pg/ml)	p-tau (pg/ml)	Method	CSF type
Agren-Wilsson et al. [12]	Sweden	iNPH	62	72 (55–83)^d	39/23	503 ± 103	171 ± 68	33 ± 10	ELISA	Lumbar
Agren-Wilsson et al. [12]	Sweden	Controls^a	23	73 (59–88)^d	10/13	716 ± 170	330 ± 179	58 ± 29
Kapaki et al. [13]	Greece	iNPH	18	69 ± 14	11/7	400 ± 219	219 (118–280)^d	34.8 (20–46.7)^d	ELISA	Lumbar
		AD	67	66 ± 10	26/41	422 ± 149	571 (443–984)^d	72 (60.4–100)^d
		Controls^a	72	64 ± 11	41/31	721 ± 228	166 (117–233)^d	45.1 (40–55.8)^d
Seppala et al. [26]	Finland	iNPH	101	NA	NA	399 ± 188	1261 ± 1354	78.1 ± 51.5	ELISA	Ventricular
Seppala et al. [26]	Finland	AD	51	75.4 ± 7.6	27/24	360 ± 202	1432 ± 1990	83.9 ± 50.1
Jeppsson et al. [25]	Sweden	iNPH	28	69 ± 6.6	15/13	221 (156–325)^d	39 (34–50)^d	39 (33–50)^d	ECL^e, xMAP	Lumbar
Jeppsson et al. [25]	Sweden	Controls^a	20	70 ± 3.6	11/9	498 (391–669)^d	84 (64–107)^d	59 (47–75)^d
Miyajima et al. [24]	Japan	iNPH	46	74.7 ± 6.9	27/19	314 ± 254	152 ± 98	24.2 ± 10.5	ELISA	Lumbar
		AD	10	78.4 ± 8.5	5/5	189 ± 116	536 ± 299	90.3 ± 32.2
		Controls^a	8	67.1 ± 6.7	2/6	255 ± 129	216 ± 138	31.6 ± 4.66
Lim et al. [27]	South Korea	iNPH	25	73.3 ± 7.0	12/13	579.8 ± 182.3	131.9 ± 77.6	27.0 ± 9.6	ELISA	Lumbar
		AD	17	72.2 ± 10.0	10/7	409.2 ± 166.1	259.6 ± 161.5	51.3 ± 28.3
		Controls^a	10	63.0 ± 6.7	3/7	691.8 ± 212.7	196.9 ± 114.4	43.0 ± 28.5
Pyykko et al. [21]	America	iNPH^b	48	NA	27/26	476 ± 203	1210 ± 1186	77.1 ± 51.7	ELISA	Ventricular
		iNPH^c	5	NA	27/26	428 ± 250	562 ± 443	50.4 ± 14.3		Ventricular
		AD	16	78.3 (54.1–85.7)^d	6/10	422 ± 259	1361 ± 1687	81.3 ± 51.2
Tsai et al. [22]	America	iNPH	11	81.36 ± 2.58	2/9	251.17 ± 92.39	475.07 ± 335.23	47.35 ± 20.24	ELISA	Lumbar
Tsai et al. [22]	America	AD	11	61.46 ± 8.24	7/4	290.33 ± 146.74	651.53 ± 276.41	79.12 ± 30.00
Schirinzi et al. [28]	Italy	iNPH	14	73.21 ± 4.63	8/6	477.50 ± 223.10	183.36 ± 99.81	25.36 ± 9.48	ELISA	Lumbar
		AD	14	69.85 ± 7.42	5/9	308.43 ± 91.38	662.79 ± 223.62	77.71 ± 21.65
		Controls^a	14	67.21 ± 7.67	8/6	862.86 ± 230.40	231.14 ± 78.42	40.50 ± 11.81
Jingami et al. [23]	Japan	iNPH	55	76.4 (7.2)	NA	NA	297 (232–440)^d	16.0 (11.3–23.7)^d	ELISA	Lumbar
Jingami et al. [23]	Japan	AD	20	71.8 (12.8)	NA	NA	932 (716–1533)^d	57.0 (32.1–102)^d

NA not available
^aHealthy controls
^bShunt responder
^cShunt nonresponder
^dData are presented as median (Q1–Q3 range)
^eElectrochemiluminescence

Back to article page

ISSN: 2045-8118

Contact us

Submission enquiries: journalsubmissions@springernature.com